Mycobacterium genavense in the Netherlands: an opportunistic pathogen in HIV and non-HIV immunocompromised patients. An observational study in 14 cases  by Hoefsloot, W. et al.
Mycobacterium genavense in the Netherlands: an opportunistic pathogen
in HIV and non-HIV immunocompromised patients. An observational
study in 14 cases
W. Hoefsloot1, J. van Ingen2, E. J. G. Peters3, C. Magis-Escurra1, P. N. R. Dekhuijzen1, M. J. Boeree1 and D. van Soolingen1,2,4
1) Department of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Nijmegen, 2) Department of Clinical Microbiology, Radboud University
Nijmegen Medical Centre, Nijmegen, 3) Department of Internal Medicine, VU University Medical Center, Amsterdam and 4) National Mycobacteria
Reference Laboratory, National Institute for Public Health and the Environment, Bilthoven, the Netherlands
Abstract
Mycobacterium genavense is an opportunistic non-tuberculous mycobacterium previously mostly associated with HIV-infected patients
with CD4 counts below 100/lL. In this retrospective observational study of medical charts we studied all Dutch patients in whom
M. genavense was detected between January 2002 and January 2010. Of the 14 patients identiﬁed, 13 (93%) showed clinically relevant
M. genavense disease. All patients with M. genavense disease were severely immunocompromised, including HIV-infected patients, solid
organ transplant recipients, those with chronic steroid use in combination with other immune modulating drugs, recipients of chemo-
therapy for non-Hodgkin lymphoma, and those with immunodeﬁciency syndromes. Two patients had non-disseminated pulmonary
M. genavense disease. Of the 12 patients treated, eight (75%) showed a favourable outcome. Four patients died in this study, three
despite treatment for M. genavense disease. We conclude that M. genavense is a clinically relevant pathogen in severely immunocompro-
mised patients that causes predominantly disseminated disease with serious morbidity and mortality. M. genavense is increasingly seen
among non-HIV immunocompromised patients.
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Introduction
Among the non-tuberculous mycobacteria (NTM), Mycobacte-
rium genavense has been described as a pathogen causing dis-
ease with signiﬁcant morbidity and mortality, especially in
HIV-infected patients with CD4 counts below 100/lL [1,2].
It was ﬁrst described by Bo¨ttger et al. in 1993 [3], and retro-
spectively ﬁrst isolated in 1987 from an HIV patient with a
disseminated infection [4].
In the period after the introduction of antiretroviral ther-
apy (cART) in the late 1990s, the epidemiology of M. gena-
vense changed. M. genavense was now acknowledged as an
opportunistic pathogen in patients with non-HIV immunode-
ﬁciencies such as solid organ transplant recipients [5–7],
patients with both innate and acquired impairment of cell-
mediated immunity, as in some lymphoproliferative malignan-
cies [8], in patients after allogeneic stem cell transplantation
[9], and patients on immunosuppressive therapy [10–13].
The available literature focuses only on case reports. Little is
known about clinical aspects, treatment and outcome in this
category of patients.
M. genavense can be isolated from tap water, healthy birds
and the gastrointestinal tract of healthy individuals. Hence, it
is important to distinguish contamination and colonization
from true infection if M. genavense is isolated from a
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE BACTERIOLOGY
non-sterile source (e.g. the digestive or respiratory tract)
[14,15]. The American Thoracic Society (ATS) has published
guidelines to assist in this distinction [16]. The clinical rele-
vance of an NTM species may be quantiﬁed by assessing the
percentage of patients with positive cultures of the respec-
tive NTM who meet the ATS diagnostic criteria.
We studied the frequency and clinical relevance of M. ge-
navense isolation in the Netherlands, using the ATS diagnos-
tic criteria. We focus on clinical aspects, treatment and
outcome of M. genavense disease.
Methods
The present study is a retrospective observational study of
all patients in the Netherlands who had M. genavense
detected in a clinical sample during the 2002–2010 period.
Patients were identiﬁed by reviewing the database of the
Dutch National Institute for Public Health and the Environ-
ment (RIVM) for clinical samples in which M. genavense was
detected. The RIVM is the national mycobacteria reference
laboratory that provides identiﬁcation and drug susceptibility
testing for all hospitals in the Netherlands. In addition, all
hospitals that perform identiﬁcation of NTM without referral
to the RIVM were contacted to include their patients with
clinical samples in which M. genavense was detected. We
reviewed medical records of all identiﬁed patients in whom
M. genavense was detected in the study period. We recorded
demographic data, clinical data, treatment and outcome. The
2007 ATS diagnostic criteria were used to determine clini-
cally relevant infections [16]; because M. genavense is extre-
mely difﬁcult to culture on routine media, we considered
molecular detection of M. genavense to equal culture, as the
ATS criteria are based on cultures. The ATS diagnostic crite-
ria are designed speciﬁcally for pulmonary NTM disease. For
non-pulmonary infections in this study, clinically relevant
infection was deﬁned by positive culture or molecular detec-
tion of M. genavense with clinical signs in accordance with
the isolation site and, if applicable, ﬁtting radiological ﬁndings.
To identify NTM, the RIVM used the INNO-LiPA Myco-
bacteria v2 (Innogenetics, Ghent, Belgium) reverse line blot
assay, which has speciﬁc probes for M. genavense. Prior to
2004, 16S rDNA gene sequencing was performed by previously
published methods [17], after ruling out membership of the
M. tuberculosis or M. avium complex using the AccuProbe
assays (GenProbe, San Diego, CA, USA). Similarly, 16S
sequencing or INNO-LiPA assays were mostly used by
the local hospitals. Drug susceptibility testing was not
performed.
The local ethics committee approved the study.
Results
We identiﬁed 14 patients in whom M. genavense was
detected in a clinical sample. Thirteen (93%) patients met the
ATS diagnostic criteria. For 11 patients, M. genavense was
detected by molecular methods only, in clinical specimens. In
three, scanty growth was observed on Middlebrook 7H10
solid (n = 1) or 7H9 liquid medium (n = 2) supplemented
with sheep blood and Mycobactin J and identiﬁed by the
INNO-LiPA Mycobacteria v2 assay as M. genavense; no
growth was observed upon subculture. Seven patients (54%)
had M. genavense detected in pulmonary samples, of whom
two had localized M. genavense disease (no other site from
which M. genavense was detected)., In 11 patients (85%),
extra-pulmonary samples including bone marrow (n = 6),
blood (2), lymph node (4), liver (2) and stool (3) yielded
M. genavense. The mean age of the patients at the time of
isolation was 54.7 years (range 33–68 years). Of the patients
with a clinically relevant M. genavense infection, four patients
were HIV positive and nine patients were immunocompro-
mised due to causes other than HIV infection.
HIV-infected patients
All four HIV-infected patients presented with disseminated
M. genavense disease. The mean CD4 count at the time of
M. genavense isolation was 35/lL (range 10–83). The patients
mostly reported fever (n = 3), malaise (2) and gastrointesti-
nal symptoms (2). In three patients enlarged abdominal
lymph nodes were observed. A pulmonary localization of
M. genavense was proven in one patient who presented with
pleural ﬂuid and multifocal nodular lesions on chest com-
puted tomography (CT). Treatment was given in all cases
and included ethambutol and clarithromycin in all patients.
In one patient rifampicin was added to the regimen. Two
patients were cured of M. genavense infection based on neg-
ative culture results and normalization of radiology results
(Table 1). One patient died after 7 months treatment. Post-
mortem examination revealed the cause of death in this
patient to be the combination of a disseminated M. gena-
vense disease and a cerebral malignancy. One patient is cur-
rently still on treatment and showed complete resolution of
M. genavense-related symptoms. As a result, a favourable
response to treatment was observed in three HIV positive
patients.
Non-HIV immunocompromised patients
M. genavense was detected in ten non-HIV patients. Nine
patients had a clinically relevant M. genavense isolation, all
of whom were diagnosed with an innate or acquired
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immunodeﬁciency. Details of the non-HIV patients with a clini-
cally relevant M. genavense isolation are summarized in Table 2.
Disseminated M. genavense disease
Seven of nine patients showed disseminated M. genavense
disease. Two patients were solid organ transplant recipients,
the other ﬁve patients were immunocompromised due to an
immunological disorder, immunosuppressive drugs or a hae-
matological malignancy (Table 2). Patient number 13, diag-
nosed with an idiopathic CD4+ T-cell lymphocytopenia, also
had Mycobacterium xenopi and Mycobacterium simiae isolated
from a bronchoalveolar lavage. Fever was the most common
clinical sign (Table 3). Pancytopenia was seen at the time of
M. genavense isolation in four cases, all of whom had M. ge-
navense isolated from bone marrow. Enlarged para-aortic and
mesenteric lymph nodes were the most common abnormali-
ties on radiological examination (n = 4), followed by pulmo-
nary dense airspace opacities (2). Six patients were treated
for M. genavense disease, of whom two died; the other
patients showed a good clinical response and are still, or
chronically treated. One patient received a treatment for a
presumed M. tuberculosis infection and died several weeks
after the start of this treatment.
Pulmonary M. genavense disease
Two patients had M. genavense detected repeatedly, but in
pulmonary samples only. They had no clinical suspicion of
other organ involvement of M. genavense (patients 5 and 6 in
Table 2). Patient 6 was free of any immune suppression at
the time of ﬁrst M. genavense detection. Fever was reported
by both patients. Other complaints were dyspnoea, produc-
tive cough and chest pain. Radiological examination showed
cavitations together with a reticulonodular pattern in both
patients (Fig. 1). Treatment was initiated in both, one was
cured and the other is still being treated.
Clinically irrelevant detection of M. genavense occured in
bronchoalveolar lavage ﬂuid obtained from a patient with a
community-acquired pneumonia who improved on a course
of amoxicillin and clavulanic acid. The patient was known to
have type 2 diabetes; he had not been using immunosuppres-
sive drugs before. No clinical signs or radiological abnormali-
ties suggestive of mycobacterial disease were found during
2 years of follow-up.
Among the 12 patients treated for M. genavense disease
(i.e. with regimens including a macrolide, ethambutol and
often rifampicin) we recorded a favourable outcome in 75%
(9/12) of patients (cured, 25% (n = 3); chronically treated
but with resolution of M. genavense-related complaints, 50%
(n = 6)); three died. Overall, four patients (4/13, 30%) died
in this study because of (disseminated) mycobacterial disease:
the three treated for M. genavense disease and one who
received treatment for presumed M. tuberculosis infection
(Tables 1 and 2).
Discussion
Mycobacterium genavense detection proved to be indicative of
clinically relevant disease in 93% (13/14) of the patients in
this study. Disseminated disease was seen in all HIV-positive
patients and in 78% of the non-HIV immunosuppressed
patients. To the best of our knowledge, we have reported
the ﬁrst two patients with a non-disseminated pulmonary
M. genavense disease. One of these patients used predniso-
lone and azathioprine, a drug combination that was also used
by one of the patients with disseminated disease. The other
patient had been on systemic steroids and had a pre-existing
pulmonary ﬁbrosis with bullae, which probably predisposed
to a pulmonary M. genavense infection. Although little is
known about the pathogenesis of M. genavense infection,
Ehlers and Richter [18] showed that immunocompetent mice
cleared intravenous-injected M. genavense, in contrast to syn-
geneic gamma-interferon-gene-deﬁcient mice. This observa-
tion is in agreement with our study, in which M. genavense-
disseminated disease was only seen in severely immunocom-
promised patients, including HIV-infected patients, solid
organ transplant recipients, those with chronic steroid use in
combination with other immune modulating drugs, recipients
of chemotherapy for non-Hodgkin lymphoma and those with
immunodeﬁciency syndromes.
TABLE 1. Individual clinical characteristics, treatment and outcome of the HIV-positive patients with M. genavense disease
Patient Age/Sex
Year of
diagnosis
CD4
count/lL Detection site
Disseminated
disease Treatment Outcome
1 33/M 2002 83 Abdominal lymph nodes. Yes E/Cla 7.5 years Cured
2 53/M 2007 52 Liver Yes E/Cla Chronic treated
3 49/M 2002 10 BM, faeces, pleural ﬂuid, ascites, lung biopsy Yes R/E/Cla 26 months Cured
4 64/M 2005 10 Faeces
Post-mortem: AFB+ material in: BM, spleen,
liver and lung
Yes E/Cla several months Died, cause of death:
MG disseminated disease
and intracerebral tumour
AFB, acid fast bacilli; BM, bone marrow; Cla, clarithromycin; E, ethambutol; Hb, haemoglobin; MG, Mycobacterium genavense; R, rifampicine.
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Prior to the cART era, M. genavense disease was predomi-
nantly seen among HIV-infected patients. Tortoli et al. retro-
spectively reviewed all patients in Italy with M. genavense
isolation between 1992 and 1996. All 24 patients appeared
to be HIV positive with a mean CD4 count of 23/lL [1].
The epidemiology seems to have changed since the introduc-
tion of cART; 71% of the patients in this study were HIV
negative. This ﬁnding is in line with the replacement of
HIV-related M. genavense case reports by non-HIV-related
M. genavense case reports identiﬁed in the literature since
the publication of Tortoli [5–13]. In the Netherlands this epi-
demiological shift has also been observed since the last liter-
ature report of HIV-related M. genavense infection was
published in this country in 1998 [19]. This epidemiological
transition probably reﬂects the rising number of indications
for the use of immunosuppressive drugs, and increasing num-
ber of solid-organ transplant recipients, together with a bet-
ter life expectancy of this group of patients. Anti-TNF
therapy is increasingly seen as one of the important immuno-
suppressive drugs that giving a higher risk of mycobacterial
disease [20,21]. However, we have not found any patient
using anti-TNF therapy. No case reports have been
described in the literature either regarding M. genavense dis-
ease related to anti-TNF therapy. TNF inhibition alone might
not be enough for M. genavense to become pathogenic in
humans.
Whether the number of HIV patients presenting with an
M. genavense infection is decreasing cannot be concluded
from our data. However, because M. genavense infection is
especially observed at CD4 counts below 100/lL, the early
initiation of cART in the disease course of an HIV patient
has certainly inﬂuenced its epidemiology; a similar phenome-
non has been noted for M. avium infections in this group
[22].
The exact environmental source of M. genavense remains
unknown. M. genavense has been found in hospital tap water
[23], and has been isolated with high bacterial load from
the intestines of apparently healthy birds [24]. Furthermore,
Dumonceau et al. [14] reported DNA isolation of M. gena-
vense from macroscopically healthy intestinal biopsy samples
in ﬁve out of nine HIV-negative patients. All these patients
were free of any clinical sign of infection. This ﬁnding sup-
ports the hypothesis that M. genavense may colonize the gut
and disseminate from it when patients become immunocom-
promised [25]. If colonization can be found in a high number
of healthy individuals, as suggested by Dumonceau, then the
risk of dissemination from the gut is low because the fre-
quency of M. genavense isolation in the Netherlands (2–4/
year) is only a small part of the total number of NTM iso-
lated (800/year) [26]. Considering the difﬁculty in culturingT
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M. genavense, underestimation of M. genavense disease inci-
dence is likely. Further study is warranted to explore the
frequency of M. genavense presence in intestines in healthy
individuals and factors associated with dissemination. Proba-
bly, HIV infection with low CD4 counts is an important risk
factor for dissemination from a colonized gut because the
Swiss HIV cohort study found M. genavense in 12.8% of the
disseminated NTM infections diagnosed between 1990 and
1992 [2].
Diagnosis of M. genavense infection remains a challenge for
clinicians because of the absence of speciﬁc symptoms and
the difﬁculties with culturing the organism using standard
mycobacterial culture methods. In an immunocompromised
host, especially with signs of disseminated disease (pancyto-
penia, abdominal lymph nodes), mycobacterial disease includ-
ing M. genavense dissemination has to be considered. Nucleic
acid ampliﬁcation techniques are useful to establish a fast and
reliable diagnosis. Attempts to culture M. genavense are
probably best carried out on solid media (Middlebrook
7H11) supplemented with blood and charcoal and acidiﬁed
to pH 6.2 ± 0.2 [27].
Before cART became available, survival from dissemi-
nated M. genavense infection was poor and comparable with
disseminated Mycobacterium avium complex (MAC) disease
with a mean survival time of 8.5 months [1,2,22,28]. After
cART was introduced, no studies were published concern-
ing treatment outcome and survival for M. genavense-
infected HIV patients. In our study, one patient died and
one patient is still being treated. Probably, as also observed
in MAC disease, survival for M. genavense improved dramat-
ically because of the combination of cART and anti-myco-
bacterial drugs. However, this has to be conﬁrmed in
future (international) studies. Little is known about factors
associated with mortality in the M. genavense-infected non-
HIV population. Delay in diagnosis and thus treatment,
ongoing immune suppression and treatment duration are
factors to be considered [8,13]. The optimal treatment reg-
imen for M. genavense disease remains unclear. In vitro sus-
ceptibility data are limited because of the fastidiousness of
the organism. Previous studies, reviewed in the ATS State-
ment, have recorded in vitro susceptibility to rifamycins,
streptomycin, macrolides, ﬂuoroquinolones and amikacin
[16]. In our study, all initiated treatments for M. genavense
consisted of clarithromycin. Ethambutol was added in nine
patients, rifampicin in eight and moxiﬂoxacin in one patient.
Current ATS guidelines only state that macrolide-based reg-
imens are preferable over other regimens; the rifampicin,
ethambutol and macrolide regimen advised for M. avium
complex disease is likely to be preferable for M. genavense
disease too. Life-long treatment was given in a high per-
centage of patients and may be indicated when the immu-
nosuppressive condition persists; otherwise, therapy may be
continued until the patient has been culture-negative for 12
consecutive months [16].
In conclusion, M. genavense is an opportunistic pathogen
in HIV and non-HIV immunocompromised patients, causing
mostly disseminated disease with serious morbidity and
mortality. After the introduction of cART, the epidemiol-
ogy has changed, with a switch to non-HIV immunocom-
promised patients. The optimal treatment regimen and
duration is unclear. Because the organism can colonize the
gut of healthy individuals, more research is needed
to determine factors associated with dissemination and
disease.
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TABLE 3. Frequency (%) of symptoms and signs in non-HIV
immune-suppressed Dutch and previously published cases
presenting with disseminated M. genavense disease [5–13]
Symptom or sign Dutch patients (n = 7) Literature (n = 9)
Fever 86 67
Weight loss 57 22
Malaise/Fatigue 57 22
Productive cough 43 22
Night sweats 29 11
Diarrhoea 29 44
Dyspnoea 29 0
Abdominal pain 14 44
Vomiting 14 0
FIG. 1. Computed tomography of patient 6. Cavitations are seen in
the right upper lobe together with a reticulonodular pattern, espe-
cially seen in the left lung.
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